Medlab Clinical Limited (MDC) 2018年年度报告「ASX」.pdf

1、Copyright Medlab Clinical Ltd 2018ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2018MEDLAB CLINICAL LIMITED(ABN 51 169 149 071)INNOVATION-QUALITY-LIFE SCIENCESCONTENTS 3 Chairmans Letter4CEO Report5Directors Report11Auditors Independence Declaration20Financial Statements21Directors Declaration49Independen

2、t Auditors Report50Shareholder Information53Corporate Directory55Medlabs Nutraceutical Range-Practitioner onlymedlab.coINNOVATION-QUALITY-LIFE SCIENCES 4 CHAIRMANS LETTERWelcome to Medlab Cli ni cals 2018 Annual Report.Three years ago,we stated i n our i ni ti al offeri ng documents that our ai m wa

3、s to develop novel nutraceuti calsand medi ci nes to treat chroni c i llness.There were fi ve areas of chroni c i llness we mapped out for concentrati on,as thi s di agram shows:Our i ntenti on was to use our knowledge i n probi oti cs and develop our uni que very small parti cle deli very system,Na

4、noCelle.It i s pleasi ng to report now that,wi thi n thi s relati vely short peri od of three years,we are well underway wi th taki ng our researchi nto human tri als.We currently have three cli ni cal tri als i n progress:Intractable Pai n,wi th NanaBi s bei ng tri alled at Royal North Shore Hospi

5、tal wi th seri ously i ll cancer pati entsDepressi on,wi th our NRGBi oti c bei ng used i n combi nati on wi th standard depressi on medi ci ne i n a Phase 2a tri al at QUTObesi ty and Di abetes,wi th Medlabs T2Bi oti c havi ng completed a Phase1a tri al and prepari ng for a Phase2a tri alIn all thr

6、ee of these tri als,Medlabs products,processes and methods are protected by patents,some granted and others pendi ng.The cancer pai n tri al i nvolves Medlab i n the medi cal cannabi s busi ness sector but wi th di sti ncti ve posi ti oni ng.We are usi ngour own formulati on of cannabi s medi ci ne